Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia

NCT02274233 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped Changes in renal function parameters.

Conditions

Iron Overload
Beta-Thalassemia

Interventions

DRUG: SP-420

Sponsor

Sideris Pharmaceuticals